Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2021Cited by 226
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatmentFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2022Cited by 100
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survivalFederica Miglietta, Valentina Guarneri, Michele Bottosso et al.|ESMO Open|2022Cited by 93
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialValentina Guarneri, Aleix Prat, Fara Brasó‐Maristany et al.|EBioMedicine|2022Cited by 42
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implicationsGaia Griguolo, Valentina Guarneri, Michele Bottosso et al.|Cancer Treatment Reviews|2021Cited by 42